Evofem Biosciences, Inc. (EVFM)
- Previous Close
0.0128 - Open
0.0125 - Bid --
- Ask --
- Day's Range
0.0125 - 0.0155 - 52 Week Range
0.0120 - 3.7500 - Volume
740,620 - Avg. Volume
844,070 - Market Cap (intraday)
684,498 - Beta (5Y Monthly) -1.16
- PE Ratio (TTM)
0.30 - EPS (TTM)
0.0500 - Earnings Date Apr 26, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
www.evofem.comRecent News: EVFM
Performance Overview: EVFM
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVFM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVFM
Valuation Measures
Market Cap
684.50k
Enterprise Value
44.06M
Trailing P/E
0.30
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.80
Price/Book (mrq)
--
Enterprise Value/Revenue
2.42
Enterprise Value/EBITDA
-2.74
Financial Highlights
Profitability and Income Statement
Profit Margin
290.81%
Return on Assets (ttm)
-62.46%
Return on Equity (ttm)
--
Revenue (ttm)
18.22M
Net Income Avi to Common (ttm)
49.99M
Diluted EPS (ttm)
0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.15M